Quanterix

Phase A — Understand the business

Lens 1 · Company Overview

Quanterix is a life-sciences tools + emerging-diagnostics company. Its core IP is Simoa ("Single Molecule Array") — a bead-based digital immunoassay that detects protein biomarkers at femtomolar concentrations, ~1,000× more sensitive than conventional ELISA, in blood/serum/CSF. The model is razor-and-blade: place an instrument (HD-X, SR-X, the new Simoa ONE), then sell recurring consumables (fully-developed assay kits + "homebrew" kits) against a growing installed base. It also runs an Accelerator Laboratory (CLIA-certified) doing contract research + four Laboratory-Developed Tests (LDTs), and is building Lucent Diagnostics (clinical Alzheimer's testing).

Hard shape of the business:

• FY2025 revenue $138.9M (vs $137.4M FY2024 — +1%, effectively flat). Net loss $107.2M (vs $38.5M — losses ~tripled).
• Installed base >2,500 instruments; >6,200 publications cite Simoa (a genuine scientific-validation moat); >2,600 Accelerator projects for >500 customers.
• 450 full-time employees; HQ Billerica, MA; fiscal year ends Dec 31; CIK 0001503274.
• Two 2025 acquisitions reshape the entity: Akoya Biosciences (spatial biology, closed Jul 8 2025, $151.0M) and Emission Inc. (dye-encapsulating magnetic beads, Jan 8 2025, $9M upfront + up to $50M earnout).

Revenue mix FY2025: Product $92.9M (67%) — instruments $17.9M + consumables/other $75.1M; Service & other $44.2M (32%); collaboration/license $1.5M (1%); grant $0.2M. Customer purchase terms: instruments are large capex sales (lumpy, RUO — research-use-only), consumables are recurring, services are fixed-fee contracts. Customer concentration is low — top-5 customers ≈14% of revenue; no single customer >10%.

The one-sentence version: a respected ultra-sensitive-protein platform with deep academic credibility, whose core research-tools demand is shrinking, trying to (a) buy growth via spatial biology and (b) cross the chasm into reimbursed clinical diagnostics.

Lens 2 · Supply Chain

Upstream → Quanterix → end customer, with named nodes:

• Inputs / suppliers: antibodies, reagents, dyes, paramagnetic beads, optical/fluidic components. Single-source / limited-source dependencies are an explicit risk — "we rely on a limited number of suppliers or, in some cases, one supplier, for some of our materials and components." All internal components are sourced domestically except one significant component (named as a foreign/single-source dependency — a tariff- and disruption-exposed chokepoint). The Emission acquisition was explicitly defensive: secure in-house supply of "highly controlled beads" for next-gen platforms rather than depend on a third party.
• Manufacturing: primary assembly at Billerica, MA; the company relies on single contract manufacturers for certain key instruments ("If any of these manufacturers should fail to perform… our ability to [supply] would be impaired") — a named chokepoint.
• The company itself: instruments (Simoa HD-X/SR-X/ONE; Akoya PhenoCycler/PhenoImager), consumable assay kits, Accelerator lab services.
• Distribution: direct field sales in North America + Europe; own salesforce + distributors across Australia, Brazil, China, Czechia, India, Hong Kong, Israel, Japan, NZ, Qatar, Saudi Arabia, Singapore, South Africa, South Korea, Taiwan, UAE. Distributor reliance outside the US is a flagged revenue risk.
• End customers: academic/research labs, CROs, biopharma (assay services + therapeutic monitoring), and — the new vector — clinical providers / neurologists via Lucent Diagnostics, plus eventual CMS / private payers as the reimbursement counterparty for LucentAD.

Chokepoints: (1) single-source component(s) + single contract manufacturers on key instruments; (2) tariff exposure on that imported component (a named 2025 headwind); (3) the Stanford-licensed IP underpinning Akoya's spatial platform (exclusively licensed — see Lens 3/10). Names present → lens passes.

Lens 3 · Competitive Advantages (moats)

What's real:

• Sensitivity + the citation flywheel. Femtomolar detection is a genuine analytical edge for low-abundance proteins (neuro biomarkers especially), and >6,200 publications create a literature lock-in: once an assay is the published standard for a biomarker (e.g. plasma pTau, NfL, GFAP), new studies default to it. That is the durable moat — scientific switching cost, not hardware.
• Installed base → consumable annuity. 2,500+ instruments seed a recurring-revenue stream; consumables are the high-quality part of the model.
• IP estate: ~154 issued patents (owned/exclusively licensed); Akoya's spatial tech is exclusively licensed from Stanford.
• Alzheimer's first-mover data: five-analyte LucentAD panel with strong clinical-validation data (intermediate-zone reduced 31.2%→10.5%) and a CMS reimbursement rate of $897 already established for LucentAD Complete.

What's weak / eroding (the bear's moat case):

• Bargaining power is thin in a down market. Instruments are discretionary capex; when academic/pharma budgets contract (NIH cuts, tariffs), customers simply defer — Quanterix has little pricing power and the moat doesn't stop the cycle.
• The diagnostics moat is contested and Quanterix is behind on clearance. Fujirebio's Lumipulse pTau217/Aβ42 plasma ratio is already the FIRST FDA-cleared blood-based Alzheimer's diagnostic; Roche+Lilly are pushing Elecsys pTau217 on high-throughput analyzers; C2N's PrecivityAD2 is commercially live. Quanterix only submitted its 510(k) in Jan/Feb 2026 — it is racing from behind, and its RUO/LDT positioning means clinical revenue is gated on clearance + payer adoption (lab billing not expected until ~2027).
• Spatial biology is a knife-fight too — 10x Genomics (Xenium), NanoString legacy/Bruker, Vizgen all compete; Akoya was a distressed asset (it had a Midcap term loan paid off at deal close — see Lens 5).

Verdict on moat: real in research proteomics (citations + sensitivity), unproven in clinical diagnostics, and not strong enough to offset a demand recession.

Lens 4 · Segments

Quanterix reports two operating segments since the Akoya deal — Simoa (legacy) and Spatial Biology (Akoya) — plus a product/service revenue cut. The segment numbers expose the whole thesis: headline growth is acquired; the core is shrinking.

Q1 2026 by platform:

Geography Q1 2026 product: roughly US $13.5M / EMEA $8.0M / APAC+other $3.9M (US ≈53%); ~42% of FY2025 receivables were international.

The organic trend across the last four prints (the single most important table in this dossier):

Cause, per management: NIH/federal research-funding cuts, new US import tariffs, and pharma R&D/clinical-trial spending pullbacks hit academic (−24% pro-forma) and pharma (−21%) demand. Decelerating-into-decline core, masked by M&A.

---

Phase B — Measure performance

Lens 5 · Earnings Result (latest print + FY2025)

FY2025 (10-K):

• Revenue $138.9M (+1%); gross margin collapsed to 46.8% from 60.5% — a 14-pt destruction, driven by lower cost absorption on falling Simoa volume + Akoya's lower-margin mix + new-assay introduction costs.
• SG&A $138.0M = 99% of revenue (vs 74%), inflated by $16.4M Akoya acquisition/integration costs + a $4.9M Emission contingent-comp charge; R&D $35.9M (26%).
• Impairment & restructuring $15.7M (goodwill impairment + severance + impaired Akoya leases). The legacy goodwill was impaired to zero mid-2025; the $26.4M goodwill on the YE balance sheet is freshly-acquired Akoya goodwill.
• Net loss $107.2M (−77% margin) vs $38.5M.
• Operating cash burn $77.2M (vs $35.2M).
• Balance sheet: $29.8M cash + $88.4M marketable securities = ~$118.2M liquidity at YE2025; no debt (Akoya's Midcap term loan was paid off at close); total assets $418.8M, total liabilities $123.0M, stockholders' equity $295.7M.

Latest print — Q1 2026 (10-Q):

• Revenue $36.4M (+20% reported / −21% organic); missed consensus ~$37.2M.
• EPS −$0.37, beat consensus −$0.47 — i.e. revenue miss, cost beat, the signature of a cost-cut story.
• GAAP gross margin 43% (down from 49% PY); adjusted GM 50.9%.
• Net loss $17.5M (improved from $20.5M — restructuring traction).
• Liquidity $99.3M ($36.2M cash + $63.1M marketable securities), no debt. Liquidity fell ~$19M QoQ — burn is moderating but not gone.
• Contingent earnout liabilities $5.7M carried (Emission performance milestones, up to $50M potential).

Guidance: FY2026 revenue $169–174M (~+23%, all Akoya); GAAP GM 41–45%, adjusted GM 49–53%; $85M of annualized cost synergies fully delivered; cash-flow breakeven targeted H2 2026, exit year with ~$100M cash, no debt. Management framed 2026 revenue as "consistent with 2025" on an underlying basis — i.e. flat-to-down organically; the growth line is the acquisition arithmetic.

Unusual vs own history: gross-margin destruction of this magnitude is the standout flag — a tools business shedding 14 points of GM in a year is losing operating leverage badly as volume falls.

Lens 6 · Earnings Calls (sentiment trend)

No transcripts on the research-layer shelf (transcripts/ empty); sentiment reconstructed from web transcript summaries.

• Tone arc: Q1 2025 — defensive, cut FY2025 guide to $120–130M, "revenue fell short." Through 2025 — pivots hard to self-help language: "$85M synergies," "cash-flow breakeven 2026," "core operating-cost reduction." Q4 2025 / Q1 2026 — declares victory on cost ("delivered the full $85M in annualized cost synergies") while still printing organic declines.
• What they keep saying: synergies, breakeven, Alzheimer's/Lucent diagnostics, "pent-up academic demand stabilizing."
• What they stopped saying: any credible organic growth narrative for the legacy Simoa research-tools franchise. The story migrated from "grow the platform" to "cut costs + win in diagnostics." That migration is itself the tell — management is no longer underwriting the core's growth.
• New-CEO framing (Cunningham, from Jan 2026) emphasizes commercial execution + diagnostics commercialization over platform science — consistent with his Illumina commercial background (Lens 9).

Lens 7 · Comps

Small-cap proteomics/spatial tools peers trade at distressed levels — several below net cash, which is the most important comp fact for QTRX. Multiples are ``/n/a; never fabricated.

Read-through: the public market is pricing the entire emerging-proteomics-tools cohort for distress / take-under, not growth. Olink and SomaLogic both exited via acquisition; Seer trades below cash. QTRX at 0.6× forward EV/Sales sits in the distressed bucket — cheap on sales, but cheap for cause (organic decline + cash burn). The bull needs it to re-rate toward a profitable-tools or a validated-diagnostics multiple; the bear notes the cohort's terminal value has repeatedly been "get acquired." Proteomics TAM is large ($40B 2026, ~10% CAGR ) but that has not rescued the tools sub-sector's multiples.

Lens 8 · Stock-Price Catalysts

QTRX is a high-beta, bad-news-driven name. Pattern over the last ~2 years:

• −64% in the year to Jul 2025 ($15.80 → $5.69); now ~$4.32, vs 52-wk range $2.40–$8.77 — near the lows, deeply de-rated from its mid-teens 2024 level.
• Down-catalysts that actually move it: revenue/guidance cuts (Q1 2025 guide-down to $120–130M was a major leg lower); margin misses; the Akoya deal announcement (read by an activist + market as dilutive); NIH-funding / tariff headlines hitting the whole life-tools sector.
• Up-catalysts: cost-synergy delivery + breakeven progress (cushioned the slide); EPS beats on cost (Q1 2026 popped pre-market on the beat ); Alzheimer's diagnostic milestones (CMS $897 rate, 510(k) submission) are the bull's catalyst path.
• What the market reacts to for this name: the gap between reported growth and organic reality, and cash runway. It rewards cost discipline at the margin but won't re-rate until either organic stabilizes or the diagnostics franchise produces real, reimbursed revenue. Macro (research-funding policy) is an outsized swing factor — this is partly a NIH-budget derivative.

---

Phase C — Judge people & books

Lens 9 · Management

A company mid-overhaul under activist pressure — the management lens is unusually load-bearing here.

• Board/founder purge: founding scientist Dr. David Walt departed the board, four prior directors left, and the board is being declassified with majority voting adopted. This was activist-driven: Kent Lake PR LLC (6.9% holder) nominated three directors and opposed the Akoya deal as "highly dilutive," settled via an Aug 4 2025 Cooperation Agreement (board refresh + governance reforms).
• CEO change: Masoud Toloue, Ph.D. resigned (termination without cause) Jan 2026; Everett Cunningham appointed President & CEO (start Jan 19 2026), previously Chief Commercial Officer of Illumina. Comp: $750K base, up to 100% bonus, $600K sign-on. Read: the board swapped a scientist-CEO for a commercial-operator-CEO — signalling the mandate is monetize + commercialize (diagnostics, sales execution), not platform R&D. Cunningham's Illumina pedigree is a double-edged credential (commercial scale experience, but Illumina itself has been a serial value-destroyer post-GRAIL).
• Capital-allocation history — poor. Cumulative net losses since inception; goodwill impaired to zero in 2025; the Akoya deal (all-cash debt payoff $82.1M + $18.9M cash + $49.9M stock = $151M) was attacked by a holder as dilutive and value-destructive, and it loaded the balance sheet with $50M of potential Emission earnouts. ROE/ROIC are deeply negative. The redeeming move: paid down all debt at the Akoya close (no leverage entering the downturn) and is executing a real $85M cost-out.
• Skin in the game: ~86% institutional ownership (AllianceBernstein, BlackRock); insider activity quiet; the most engaged owner is the activist. Founder ownership/alignment has decreased with Walt's exit.
• Archetype: transitioning from founder/scientist-led to professional-manager / activist-supervised turnaround. For this stage (broken growth story, cash-conscious, diagnostics pivot) a commercial operator is arguably the right archetype — but it is an unproven, brand-new team executing a turnaround in a hostile demand environment.

Lens 10 · Forensic Red Flags

Ground: financials.csv/segments.csv are header-only on the shelf, so all figures below are pulled directly from the filings.

• Internal-control history — the single biggest accounting flag. Quanterix disclosed material weaknesses in ICFR for FY2022, FY2023 AND FY2024 (three consecutive years), now claimed remediated as of YE2025; management/auditor concluded disclosure controls were "effective" at Dec 31 2025. The 10-K explicitly cautions additional weaknesses "may arise or be identified." Three straight years of material weaknesses + a fresh, never-stress-tested finance team + two acquisitions to integrate = elevated misstatement risk. Watch this every quarter.
• Earnings vs cash quality: net loss $107.2M vs operating cash burn $77.2M in FY2025 — the gap is non-cash (goodwill impairment, SBC, D&A, acquisition accounting). SBC $4.5M in Q1 2026 alone flatters adjusted/non-GAAP gross margin (GAAP 43% vs adj 50.9%) — the adjusted-GM headline is the one to discount.
• Acquisition accounting / contingent consideration: Level-3 contingent liabilities (Emission earnout, up to $50M; PKI License) are fair-valued and will swing the P&L; a $4.9M Emission contingent-comp charge already hit FY2025 SG&A. Goodwill of $26.4M sits on the books one impairment cycle after the last goodwill was written to zero — re-impairment risk is live if Akoya underperforms.
• Revenue-recognition surface: multi-element ASC 606 contracts (instrument + installation + warranty + consumables + extended service), plus a mid-quarter accounting-principle change reclassifying certain costs into cost-of-product-revenue (stated immaterial to net loss) — benign but worth noting as a presentation change during a turnaround.
• Going-concern: management asserts liquidity sufficient for ≥12 months; no going-concern qualification. But with ~$99M liquidity, ~$17.5M quarterly net loss, and breakeven only targeted H2 2026, the runway is real but not generous — a missed-breakeven path points to a dilutive raise.

Regulatory findings (required):

• SEC: No Litigation Releases or AAERs name Quanterix (verified via SEC EDGAR EFTS LR + AAER, 2021-06-29 → 2026-06-29).
• Non-SEC (FTC/DOJ/FDA/etc.): web search surfaced no enforcement actions, consent decrees, or penalties. FDA interactions are product-clearance (LucentAD 510(k) pending), not enforcement.
• 10-K Item 3 (Legal Proceedings): "In the ordinary course of business, we are from time to time involved in lawsuits, claims, investigations… intellectual property, contractual, employment, and other matters" — no material litigation disclosed.
• Conclusion: No material regulatory or legal findings — verified via SEC EDGAR EFTS (LR, AAER), web search, and 10-K Item 3 as of 2026-06-29. The accounting risk here is the ICFR material-weakness history, not any enforcement record.

---

Phase D — Project & stress-test

Lens 11 · Forward Projection

Operating-company EPS path. Quanterix is loss-making, so the scoreable variable is revenue + the path to breakeven, with EPS staying negative across the window. No forecast.ts create in the watchlist loop (per skill rules). All outputs `` with arithmetic; anchored to FY2025 actuals + FY2026 guide.

Anchor: FY2026 guide $169–174M rev (~$171M mid), GAAP GM 41–45%, opex cut to deliver breakeven H2 2026, ~47–48M shares, no debt, ~$99M liquidity.

The forecast that matters is not EPS — it's the binary: Does QTRX reach cash-flow breakeven in H2 2026 without an equity raise? Base case yes, narrowly (guidance + delivered synergies + ~$99M buffer make it plausible). Bear case no → a raise near ~$4 is highly dilutive on a ~$200M cap. If logging a Brier forecast (outside the loop), the scoreable line would be: "QTRX achieves positive operating cash flow in any quarter of H2 2026, p≈0.55."

Lens 12 · Bull vs Bear

Bull case. A scientifically-validated ultra-sensitive platform (6,200+ citations, the published standard for key neuro biomarkers) trading at ~0.6× forward sales with no debt and ~$99M cash, where (a) the $85M cost-out is delivered and breakeven is in sight, (b) the academic-funding trough is cyclical, not terminal — when NIH/pharma budgets normalize the consumable annuity re-accelerates off a 2,500-instrument base, and (c) there is a free option on Alzheimer's diagnostics: 510(k) filed, CMS already at $897/test, strong clinical data, a 55M-patient disease, and the secular tailwind of anti-amyloid therapies (Leqembi/Kisunla) creating demand for cheap blood-based triage. If even one of "organic stabilizes" or "LucentAD becomes reimbursed revenue" hits, a sub-$200M EV re-rates materially. Contrarian view the market refuses to see: the spatial-biology asset (Akoya) — bought cheap out of distress and now cost-rationalized — could be the part that quietly works, while everyone fixates on the Simoa decline.

Bear case (permanent-impairment risks). (1) The core is in structural, not cyclical, decline — −36%/−22%/−21% organic is not a wobble; if US research funding is permanently lower and pharma keeps cutting, the consumable annuity shrinks and the platform's relevance fades. (2) Diagnostics is a from-behind race against cleared competitors — Fujirebio is FDA-cleared, Roche/Lilly and C2N are live; Quanterix could spend years and cash to reach a commoditized, low-margin testing market where it is not the leader. (3) Acquisition-driven growth masks the rot and burns the balance sheet — strip Akoya and the company is a shrinking, cash-burning sub-scale tools business; another impairment or a dilutive raise is plausible.

Pre-mortem (18 months out, thesis broke): It's late 2027. Breakeven slipped because organic kept falling and Akoya synergies plateaued; LucentAD's 510(k) was delayed and reimbursed volume is negligible; cash fell under $50M and the company raised equity at ~$3, diluting holders ~25%. The market re-rated it to a below-cash, "next take-under" multiple alongside Seer.

Are multiples too high? No — at ~0.6× forward sales it is optically cheap. The risk isn't a high multiple; it's that the denominator (sales) is acquired and the organic base keeps shrinking, so "cheap" is a value trap unless the trajectory inflects.

Lens 13 · Devil's Advocate (short-seller)

Dismantling the bull case.

• Revenue concentration shifted to acquisition arithmetic. The only reason the top line grows is Akoya consolidation. Lap the deal (post-Jul 2026) and reported growth collapses toward the organic line, which is negative. The "+23% FY2026" guide is an accounting artifact; on the Q3 2026 call the comp gets ugly.
• The moat is academic, the money is moving clinical, and they're losing the clinical race. Citation lock-in doesn't pay if research budgets shrink; the reimbursed-diagnostics prize is being taken by Fujirebio (cleared), Roche/Lilly, C2N — Quanterix has only submitted a 510(k) and won't bill meaningfully until ~2027. RUO/LDT positioning is where you go when you can't get cleared fast.
• Most dangerous competitor bulls underrate: Roche + Lilly. A high-throughput Elecsys pTau217 on Roche's installed analyzer base, marketed alongside Lilly's Kisunla, can scale clinical Alzheimer's testing far faster than a sub-scale Simoa lab — and crush the price.
• Capital allocation has been value-destructive: serial losses, goodwill impaired to zero, an acquisition an engaged holder called "highly dilutive," and up to $50M of Emission earnouts layered on. New, unproven CEO + brand-new board executing the turnaround.
• Accounting: three consecutive years of ICFR material weaknesses; non-GAAP gross margin leans on ~$4.5M/quarter SBC and adjustments; fresh acquisition accounting + contingent-consideration marks make reported numbers noisy.
• What must hold for ~$4: organic stops falling, breakeven lands H2 2026 without a raise, and LucentAD becomes real revenue. If FY2027 organic still declines 15–20%, fair value is below cash (~$2 handle) — exactly where Seer trades. The single permanent-impairment scenario: structurally lower research funding + a lost diagnostics race → the platform becomes a melting ice cube and the equity is recapitalized. Plausibility: moderate-to-high on the funding leg, moderate on the diagnostics leg.

Lens 14 · Management Questions (ordered by information value)

1. Strip out Akoya entirely — what is your honest organic Simoa growth assumption for 2026 and 2027, and at what quarter do you expect organic to inflect positive?
2. Breakeven without a raise: what cash balance do you exit 2026 with in the bear case, and what is the trigger point at which you would raise equity?
3. On LucentAD: timeline to 510(k) clearance, to first reimbursed billing, and your realistic 2027/2028 clinical-diagnostics revenue range — what gets you paid vs. Fujirebio (already cleared), Roche/Lilly, and C2N?
4. Why should investors believe the research-funding decline is cyclical, not structural — what in your bookings/pipeline supports a recovery rather than a permanently smaller academic TAM?
5. After three consecutive years of material weaknesses, what specifically changed in 2025 to remediate, and how confident are you no new weakness emerges while integrating two acquisitions?
6. Was the Akoya acquisition the right use of capital and balance-sheet vs. returning cash or doubling down on diagnostics, as Kent Lake argued? Defend the dilution.
7. What is the realistic peak revenue and margin of the Spatial Biology segment, and is it gaining or losing share to 10x Xenium / Bruker?
8. With $85M of synergies delivered, where does normalized gross margin and opex settle at scale — what's the steady-state operating model?
9. What is your pricing power on consumables in a down market — are you discounting to hold volume, and what does that do to the consumable-annuity margin?
10. CEO mandate: Mr. Cunningham, given your Illumina commercial background, is this a sell-more story or a fix-the-science story — and what's your 24-month operating priority stack?
11. Single-source components and single contract manufacturers on key instruments — what's the tariff and supply-disruption exposure, and what de-risking is underway beyond Emission?
12. What are the Emission earnout assumptions baked into guidance, and what milestones trigger the up-to-$50M payments?
13. Capital-return / strategic-alternatives: at a sub-$200M cap with no debt and ~$99M cash, has the board evaluated a sale or merger, and what would change that calculus?
14. How are you investing in AI for assay development / multi-analyte algorithms (LucentAD is algorithmic) — is this a differentiator or table stakes?
15. What is the next-gen Simoa ONE adoption curve, and does it expand the installed base fast enough to offset legacy attrition?

---